FOR JOURNALISTS AND MEDIA REPRESENTATIVES ONLY
Astellas data presentations
At the virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which took place between December 5-8 2020, nine Astellas-sponsored abstracts were presented. The nine abstracts, comprised of five oral presentations, three posters and one online-only presentation, focused on adult patients with acute myeloid leukaemia (AML) with a positive FLT3 mutation.
Further information on the Astellas-sponsored abstracts at ASH can be found via the press release.
Astellas to Present New Data on XOSPATA™▼ (gilteritinib) in adult FLT3 Mutation-Positive Acute Myeloid Leukaemia at the 2020 American Society of Hematology Annual Meeting
The below media materials are available for download and provide supporting background information on AML and FLT3 mutations.
Understanding AML backgrounder
An overview of AML, its symptoms, and how it can be treated.
Importance of FLT3 Mutation Testing in AML factsheet
An overview of the different types of mutations associated AML, the process of mutation testing and why it’s important to test for mutations in AML management.
Alisdair’s story: The need for AML research and new treatment options
Alisdair, an AML patient, shares his experience of AML, what research means to him and the need for new treatment options.
Dr. Robert Sands: Astellas’ recent progress in AML research
Astellas’ Executive Medical Director and Head of Oncology, EMEA, Dr. Robert Sands discusses the recent progress Astellas has made in AML research, including the Astellas-sponsored data presented at ASH and what it means for AML patients.
Do you have a media enquiry relating to Astellas at ASH 2020? Contact the EST-C press office via email on
ONC_2020_0240_UK. December 2020